First human tests begin for potential brain disease drug
NCT ID NCT06625710
Summary
This was an early-stage study to check the safety and see how the body processes a new drug called GV1001, which is being developed for brain diseases. It involved 59 healthy volunteers who received either the drug or a placebo as a single shot or multiple shots over several weeks. The main goal was to find out if the drug was safe and how it moved through the body at different doses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURO-DEGENERATIVE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.